title: OCT angiography in the management of choroidal neovascular membrane secondary to Sorsby fundus dystrophy.
abstract: We describe the management of a woman aged 52 years with molecularly confirmed Sorsby fundus dystrophy, who presented with acute visual deterioration in her right eye. Fundus examination identified a right macular lesion suggestive of a choroidal neovascular membrane (CNVM). Optical coherence tomography angiography (OCTA) confirmed the presence of a CNVM. She was treated with 2 monthly intravitreal injections of bevacizumab, associated with OCTA evidence of regression of the CNVM and improvement in her visual acuity. OCTA is a novel, non-invasive method of imaging the retinal vasculature. Images are acquired rapidly, with no associated side effects, offering advantages over the current gold standard technique-fundus fluorescein angiography.
authors: Moorfields Eye Hospital NHS Foundation Trust, London, UK.
authors: Aditi
authors: A
authors: Mohla
authors: Moorfields Eye Hospital NHS Foundation Trust, London, UK UCL Institute of Ophthalmology, London, UK.
authors: Kamron
authors: K
authors: Khan
authors: Moorfields Eye Hospital NHS Foundation Trust, London, UK UCL Institute of Ophthalmology, London, UK.
authors: Melissa
authors: M
authors: Kasilian
authors: Moorfields Eye Hospital NHS Foundation Trust, London, UK UCL Institute of Ophthalmology, London, UK.
authors: Michel
authors: M
authors: Michaelides
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000068258:Bevacizumab / Q000627:therapeutic use; D002829:Choroid / Q000098:blood supply / Q000000981:diagnostic imaging* / Q000473:pathology; D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000209:etiology; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D008268:Macular Degeneration / Q000150:complications*; D008875:Middle Aged; D041623:Tomography, Optical Coherence; D014786:Vision Disorders / Q000175:diagnosis / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000209:etiology; D014792:Visual Acuity
chemical_list: D020533:Angiogenesis Inhibitors; D000068258:Bevacizumab